Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;32(3):178-83.
doi: 10.1159/000446052. Epub 2016 Jun 7.

Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives

Julian Holch  1 , Sebastian Stintzing  2 , Volker Heinemann  1
Affiliations
Review

Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives

Julian Holch et al. Visc Med. 2016 Jun.

Abstract

Palliative chemotherapy for metastatic colorectal cancer has undergone substantial changes in recent years. The implementation of modern biologicals in the treatment has substantially improved overall survival up to 30 months. With the increasing number of therapeutic options, the question of optimal treatment sequence arises, which is addressed in current studies like FIRE 4 or STRATEGIC-1. Furthermore, clinical and molecular biomarkers to predict efficacy and tolerability are urgently needed. Today, the detection of activating RAS mutations is the only validated biomarker which precludes patients from anti-EGFR treatment. The detection of BRAF mutation V600E is associated with a very poor prognosis corresponding to a survival of 9-12 months. Prospective trials evaluating an optimal approach to this subgroup are still missing. First results from strategies targeting the aberrant signal transduction are promising and require further validation. Despite the advances so far, life expectancy unfortunately continues to be limited in the majority of patients with metastatic colorectal cancer. New strategies are needed to improve the prognosis. To this end, the identification of Her2/neu as a potential target and first experiences with checkpoint inhibition in patients with mismatch repair-deficient tumors are promising and also require further validation.

Keywords: BRAF mutation; Metastatic colorectal cancer; Palliative chemotherapy; RAS mutation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Possible approach to choose first-line treatment for patients with mCRC (adapted according to the ESMO Pocket Guidelines 2015 Lower Gastrointestinal Cancer, Section metastatic colorectal cancer). FP = Fluoropyrimidin; CT = chemotherapy.
Fig. 2
Fig. 2
Study design of the FIRE-4 (AIO KRK-0114) trial.
See this image and copyright information in PMC

References

    1. Robert Koch-Institut (Hrsg), Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg) Krebs in Deutschland 2011/2012. ed 10. Berlin: 2015.
    1. Bruckner HW, Motwani BT. Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol. 1991;18:443–461. - PubMed
    1. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420–1425. - PubMed
    1. Modest DP, Hiddemann W, Heinemann V. Chemotherapy of metastatic colorectal cancer (article in German) Internist (Berl) 2014;55:37–42. - PubMed
    1. Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Mohler M, Jung A, Kirchner T, Heinemann V. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol. 2015;33:3718–3726. - PubMed